Please Wait
Applying Filters...
menu
    • menu
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    AbbVie Contract Manufacturing partners globally to develop, scale, and manufacture pharmaceutical products successfully.

    Virtual Booth

    Contact Supplier

    Topscience Biotech is a one-stop supplier of sodium hyaluronate//drug manufacturing license, CEP, GMP, DMF, and Form 41 certifications.

    Virtual Booth

    Contact Supplier

    Zach System is committed to providing Highly Customized Solutions for all your Development Programs.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Eptinezumab

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Lundbeck Presents VYEPTI and Bocunebart Migraine Data at AHS
    Lundbeck Presents VYEPTI and Bocunebart Migraine Data at AHS

    04 Jun 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260603223857/en/Lundbeck-Presents-New-VYEPTI-eptinezumab-jjmr-and-Bocunebart-Migraine-Data-at-the-American-Headache-Society-68th-Annual-Scientific-Meeting

    BUSINESSWIRE
    04 Jun 2026
    Share Share
    Lundbeck's Vyepti Approved in South Korea for Migraine Prevention
    Lundbeck's Vyepti Approved in South Korea for Migraine Prevention

    26 May 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/lundbeck-receives-marketing-authorization-for-vyepti-eptinezumab-in-south-korea-for-the-preventive-treatment-of-migraine-302781558.html

    PR NEWSWIRE
    26 May 2026
    Share Share
    Lundbeck Unveils AAN 2026 Data Showing VYEPTI Impact On Migraine
    Lundbeck Unveils AAN 2026 Data Showing VYEPTI Impact On Migraine

    19 Apr 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/lundbeck-presents-new-data-at-aan-2026-highlighting-real-world-changes-in-migraine-related-cognitive-symptoms-after-starting-vyepti-eptinezumab-302746649.html

    PR NEWSWIRE
    19 Apr 2026
    Share Share
    Lundbeck Shows VYEPTI Improves Migraine Cognition at AAN
    Lundbeck Shows VYEPTI Improves Migraine Cognition at AAN

    19 Apr 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260419426923/en/Lundbeck-Presents-New-Data-at-AAN-2026-Highlighting-Real-World-Changes-in-Migraine-Related-Cognitive-Symptoms-After-Starting-VYEPTI-eptinezumab-jjmr

    BUSINESSWIRE
    19 Apr 2026
    Share Share
    Lundbeck Presents Vyepti Data on Severe Migraine at HCOP
    Lundbeck Presents Vyepti Data on Severe Migraine at HCOP

    30 Jan 2026

    // PR NEWSWIRE BIO

    https://www.prnewswire.com/news-releases/lundbeck-presents-new-real-world-data-highlighting-meaningful-improvements-in-patients-severely-impacted-by-migraine-initiating-vyepti-eptinezumab-at-hcop-annual-conference-302675109.html

    PR NEWSWIRE BIO
    30 Jan 2026
    Share Share
    Lundbeck Files for Marketing Authorization Across for Vyepti
    Lundbeck Files for Marketing Authorization Across for Vyepti

    14 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/lundbeck-files-for-marketing-authorization-across-key-asian-markets-for-vyepti-eptinezumab-for-the-preventive-treatment-of-migraine-302615423.html

    PR NEWSWIRE
    14 Nov 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.